| Affiliation: | 1. Department of Neurology, University of Virginia, , Charlottesville, VA, USA;2. MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, , London, UK;3. Department of Neurology, College of Medicine, University of Iowa, , Iowa City, IA, USA;4. Clinic of Central and Peripheral Degenerative Neuropathies Unit, Department of Clinical Neurosciences, IRCCS Foundation, C. Besta Neurological Institute, , Milan, Italy;5. Department of Neurology, Adelaide & Meath Hospitals incorporating the National Children's Hospital, Trinity College Dublin, , Dublin, Ireland |
| Abstract: | Charcot‐Marie‐Tooth Neuropathy Score second version (CMTNSv2) is a validated clinical outcome measure developed for use in clinical trials to monitor disease impairment and progression in affected CMT patients. Currently, all items of CMTNSv2 have identical contribution to the total score. We used Rasch analysis to further explore psychometric properties of CMTNSv2, and in particular, category response functioning, and their weight on the overall disease progression. Weighted category responses represent a more accurate estimate of actual values measuring disease severity and therefore could potentially be used in improving the current version. Copyright © 2014 John Wiley & Sons, Ltd. |
